Introduction
============

Cervical cancer is the third most common cancer and the fourth leading cause of cancer-related deaths among women worldwide.[@b1-ott-8-1355] For patients with locally advanced cervical cancer (International Federation of Gynecology and Obstetrics \[FIGO\] stage Ib1--IIa), radiotherapy and radical hysterectomy are effective treatment options.[@b2-ott-8-1355] Because the classification of cervical cancer patients can help predict the risk of recurrence and thus aid in providing individualized therapies that lead to an improvement in clinical outcomes, the roles of prognostic and predictive biomarkers have become increasingly important. However, the use of biomarkers is currently limited primarily to clinicopathological prognostic factors, including the histological grade, the pathological type, the number of metastatic lymph nodes, and venous and lymphatic, or perineural invasion levels. Only one cancer-specific antigen, the squamous cell carcinoma antigen, is used in cervical squamous carcinoma, and new biomarkers that are inexpensive and technically feasible are needed.

It is well known that inflammation plays a critical role in the pathogenesis and progression of cervical cancer. A large number of inflammatory/immune cells are found in the tumor stroma; these cells include tumor-associated macrophages (TAMs), lymphatic vascular endothelial cells, tumor-infiltrating lymphocytes (TILs), and other inflammatory/immune cells.[@b3-ott-8-1355],[@b4-ott-8-1355] These cells and the various inflammatory cytokines that they secrete interact with tumor cells and ultimately create a cancer-related inflammatory microenvironment.[@b5-ott-8-1355],[@b6-ott-8-1355] This environment promotes cancer angiogenesis and metastasis and alters the responses to hormones and chemotherapeutic agents.[@b7-ott-8-1355] Furthermore, the inflammatory response to tumors may contribute to the regulation of the host immune response and lead to changes in blood constituents, specifically the neutrophilic, lymphocytic, and monocytic types of white blood cells.

The preoperative lymphocyte/monocyte ratio (LMR) has been shown to be a potential prognostic marker in patients with various types of malignancies,[@b8-ott-8-1355]--[@b10-ott-8-1355] as have the neutrophil/lymphocyte ratio (NLR) and the absolute count of neutrophils divided by the absolute white cell count minus the absolute count of neutrophils (dNLR).[@b11-ott-8-1355],[@b12-ott-8-1355] Based on the above findings, our study evaluated the effects of the preoperative LMR on recurrence-free survival (RFS) and overall survival (OS) in stage Ib1--IIa cervical cancer patients.

Materials and methods
=====================

Patients and methods
--------------------

Patients with FIGO stage Ib1--IIa cervical cancer who underwent an operation between January 2004 and December 2008 at Shandong Cancer Hospital and Institute, Jinan, People's Republic of China, were included in this retrospective study. Nineteen patients (3.8%) were excluded because they had an active infection or chronic inflammatory disease, received neoadjuvant therapy, or did not have available follow-up data; therefore, 485 patients were included in the final study. All of the patients were classified according to the FIGO clinical staging system. Clinical features, including the treatment scheme (surgery, radiotherapy, and/or chemotherapy) and histopathological information, were retrospectively obtained from the patients' records. The laboratory data, which were obtained prior to treatment and within 2 days after admission, included the absolute neutrophil count, absolute lymphocyte count (ALC), and absolute monocyte count (AMC). This study was approved by the ethics committee of Shandong Cancer Hospital and Institute. Written informed consent was obtained from all of the patients prior to treatment.

Treatment schedule
------------------

All of the patients with FIGO stage Ib1--IIa cervical cancer underwent a radical abdominal hysterectomy and systematic bilateral pelvic lymphadenectomy. In patients with suspicious para-aortic lymph node metastasis, para-aortic lymph node dissection was performed. Postoperative platinum-based adjuvant chemotherapy with or without concurrent radiotherapy (pelvic external radiotherapy combined with vaginal intracavitary irradiation) was performed depending on the postoperative pathology. Two or three cycles of chemotherapy were permitted.

Follow-up evaluation
--------------------

Follow-up was performed until June 2014. The follow-up examinations were performed at regular intervals (3-month intervals during the first 2 years, 6-month intervals in years 3--5, and annually thereafter). The examinations included a physical and pelvic examination, laboratory analyses, and imaging methods (magnetic resonance imaging, abdominal ultrasound, chest X-ray, computed tomography, and/or positron emission tomography--computed tomography).

Statistical analyses
--------------------

The primary endpoint of the study was RFS (the time from diagnosis to tumor recurrence). The secondary endpoint was OS (the time from diagnosis to death by any cause). By applying a receiver operating characteristic (ROC) curve analysis, the optimal cutoff values for the ALC, AMC, and LMR were determined. The relationships between the LMR and other clinicopathological features were studied using Pearson's chi-square test or Fisher's exact test. Clinicopathological features, including the ALC, AMC, and LMR, were analyzed using Kaplan--Meier curves and compared using a log-rank test. All the clinicopathological variables associated with the RFS and OS were analyzed in the univariate analysis. The prognostic factors that had significant prognostic value in the univariate analysis were included in the multivariate Cox regression analysis. The hazard ratios (HRs) estimated from the Cox analysis were reported as relative risks with corresponding 95% confidence intervals (CIs). The correlations between the LMR and the ALC and AMC were evaluated by applying a Pearson correlation analysis. All of the statistical analyses were performed using the Statistical Package for Social Sciences (SPSS) version 13.0 (SPSS Inc., Chicago, IL, USA). A two-sided *P*\<0.05 was considered statistically significant.

Results
=======

The clinicopathological variables are shown in [Table 1](#t1-ott-8-1355){ref-type="table"}. The median age at the time of diagnosis was 45 years. The median follow-up time was 75 months (range, 10--118 months). The mean ALC and AMC values ± standard error (SE) were (1.91±0.03)×10^9^/L and (0.52±0.01)×10^9^/L, respectively. The mean LMR value ± SE was 4.50±0.14. Combined with the recent results from studies of various cancers, we hypothesized that the ALC, AMC, and LMR would have similar prognostic values for predicting the clinical outcome; therefore, we evaluated the effects of the ALC, AMC, and LMR by applying these values to the ROC curves. For the ALC, AMC, and LMR, the areas under the curve were 0.576, 0.611, and 0.640, respectively, for the RFS and 0.597, 0.603, and 0.647, respectively, for the OS. The ROC curves for the RFS are shown in [Figure 1](#f1-ott-8-1355){ref-type="fig"}. By applying an ROC analysis, the optimal cutoff levels for the ALC, AMC, and LMR were found to be 2.16×10^9^/L, 0.60×10^9^/L, and 2.87, respectively, for RFS and 2.14×10^9^/L, 0.51×10^9^/L, and 4.16, respectively, for OS. We selected the cutoff point for RFS as the uniform point for the following survival analyses.

To investigate whether the LMR is associated with the clinical outcomes of the cervical cancer patients, univariate and multivariate analyses were performed. [Figures 2](#f2-ott-8-1355){ref-type="fig"} and [3](#f3-ott-8-1355){ref-type="fig"} show the Kaplan--Meier curves, which reveal that an increased LMR is a consistent factor predicting less recurrence and a good prognosis in stage Ib1--IIa cervical cancer patients who undergo radical surgery (*P*\<0.001, log-rank test). The tumor grades were classified as G1, G2 or G3, and the tumor stages were classified as Ib1, Ib2 or IIa in the analyses. We found significant associations between age, tumor grade, lymphovascular space invasion, tumor invasion depth, lymph node metastasis, tumor stage, and adjuvant therapy and the RFS and OS in the univariate analyses (all *P*\<0.05) ([Tables 2](#t2-ott-8-1355){ref-type="table"} and [3](#t3-ott-8-1355){ref-type="table"}). We also observed a significant association between both the depth of stromal invasion and lymph node metastasis and the RFS in the multivariate analysis (all *P*\<0.05) ([Table 2](#t2-ott-8-1355){ref-type="table"}). Multivariate analysis also demonstrated a similar association between lymph node metastasis and the OS (*P*\<0.001) ([Table 3](#t3-ott-8-1355){ref-type="table"}). Other clinicopathological features were not significantly associated with the RFS or OS.

In the univariate analysis, an elevated preoperative LMR was significantly associated with an increased RFS (HR, 0.373; 95% CI: 0.247--0.563; *P*\<0.001) ([Table 2](#t2-ott-8-1355){ref-type="table"}), and this result remained significant in the multivariate analysis (HR, 0.439; 95% CI: 0.279--0.693; *P*\<0.001) ([Table 2](#t2-ott-8-1355){ref-type="table"}). In the univariate analysis, an elevated LMR was also significantly associated with an increased OS (HR, 0.381; 95% CI: 0.233--0.622; *P*\<0.001) ([Table 3](#t3-ott-8-1355){ref-type="table"}), and this result remained significant in the multivariate analysis (HR, 0.417; 95% CI: 0.244--0.714; *P*=0.001) ([Table 3](#t3-ott-8-1355){ref-type="table"}).

After the nonparametric tests were applied, our study showed that the LMR was significantly associated with the age at diagnosis (*P*\<0.001), tumor stage (*P*=0.012), parametrial involvement (*P*=0.022), and adjuvant therapy (*P*\<0.001). There were no other clinicopathological parameters associated with the LMR (all *P*\>0.05).

Among the 485 cervical cancer patients, 91 (18.8%) developed tumor recurrence, and 64 (13.2%) died during the follow-up period. Tumor recurrence was diagnosed in 47 (31.5%) out of 149 patients with an LMR ≤2.87 and in 44 (13.1%) out of 336 patients with an LMR \>2.87 (*P*\<0.001). Death occurred in 33 (22.1%) patients with an LMR ≤2.87 and in 31 (9.2%) patients with an LMR \>2.87 (*P*\<0.001).

For further analysis of the prognostic value of LMR, we explored the mean value (4.50) as the cut-off point for testing. An elevated preoperative LMR was significantly associated with increased RFS in the univariate (HR, 0.485; 95% CI, 0.295--0.797; *P*=0.004) and multivariate (0.531; 95% CI, 0.319--0.884; *P*=0.015) analysis. Additionally, a significant association between LMR and OS was observed in the univariate (HR, 0.393; 95% CI, 0.210--0.736; *P*=0.004) and multivariate (HR, 0.400; 95% CI, 0.211--0.758; *P*=0.005) analysis. The recurrence rate was 22.8% (71/312) in patients with an LMR ≤4.50 and 11.6% (20/173) in patients with an LMR \>4.50. Death occurred in 52 (16.7%) patients with an LMR ≤4.50 and in 12 (6.9%) patients with an LMR \>4.50.

In the univariate analysis, an elevated ALC was significantly associated with an increased RFS (HR, 0.288; 95% CI: 0.149--0.556; *P*\<0.001) and an increased OS (HR, 0.296; 95% CI: 0.135--0.648; *P*=0.002), whereas an elevated AMC was significantly associated with a decreased RFS (HR, 2.253; 95% CI: 1.493--3.401; *P*\<0.001) and a decreased OS (HR, 2.196; 95% CI: 1.344--3.589; *P*=0.002). In the multivariate analysis, an elevated preoperative ALC was significantly associated with an increased RFS (HR, 0.403; 95% CI: 0.199--0.815; *P*=0.011) and an increased OS (HR, 0.407; 95% CI: 0.177--0.939; *P*=0.035), whereas an elevated AMC was significantly associated with a decreased RFS (HR, 1.750; 95% CI: 1.127--2.715; *P*=0.013) and OS (HR, 1.862; 95% CI, 1.109--3.126; *P*=0.019). The LMR was not included in the multivariate analysis simultaneously because this value was derived from the ratio of the AMC to the ALC and thus was significantly related to the AMC (correlation *r*=0.432; *P*\<0.001) and the ALC (correlation *r*=0.591; *P*\<0.001).

Discussion
==========

Several explanations for the association between the LMR and the clinical outcome of cancer patients have been postulated. Lymphocytes act as basic components of the immune system, and decreased lymphocytes in the blood and in the tumor stroma lead to a down regulation of the immune response against the tumor.[@b13-ott-8-1355]--[@b16-ott-8-1355] Moreover, decreased proportions of tumor-infiltrating CD4^+^ T-cells with reversed CD4/CD8 ratios are significantly related to tumor growth and lymph node metastasis in cervical cancer.[@b17-ott-8-1355] Therefore, lymphocytopenia has been found to be an independent prognostic factor for OS in cancers such as hepatocellular carcinoma and nasopharyngeal carcinoma.[@b18-ott-8-1355],[@b19-ott-8-1355] We found that an elevated ALC was significantly associated with decreased RFS and OS in stage Ib1--IIa cervical cancer patients.

Recent studies suggest that, compared with the ALC, the neutrophil count is related to increased tumor aggressiveness. Considering the NLR and dNLR, recent studies have found that the dNLR has a similar but slightly lower prognostic value compared with the NLR.[@b11-ott-8-1355],[@b12-ott-8-1355] Absenger et al and Dalpiaz et al suggest that monocytes, which are included in the dNLR but not in the NLR, may be responsible for the difference.[@b11-ott-8-1355],[@b12-ott-8-1355] In various cancers, monocytes are associated with a poor clinical outcome and modulate the tumor microenvironment, notably by inducing an aggressive phenotype and producing survival/growth factors.[@b10-ott-8-1355],[@b20-ott-8-1355] Moreover, macrophages in the tumor stroma are differentiated from monocytes in human serum. By co-culturing with macrophages, the aggressiveness of cancer cell lines can be effectively enhanced.[@b21-ott-8-1355] Patients with a low TAM density have a significantly better disease-free survival prognosis than those with a high TAM density.[@b22-ott-8-1355] Tumor infiltration is significantly related to VEGF expression and microvessel density.[@b4-ott-8-1355] Therefore, monocytes have been suggested to play a role similar to that of neutrophils in the immune response to tumors, in opposition to the role of lymphocytes. Recent studies suggest that the LMR is a prognostic factor similar to the NLR in terms of its ability to predict the clinical outcome of several cancers.[@b9-ott-8-1355],[@b10-ott-8-1355] Our studies show, for the first time, that an increased AMC is significantly associated with a poor prognosis in stage Ib1--IIa cervical cancer patients who undergo a radical operation.

To the best of our knowledge, this study is the first to evaluate the influence of the LMR on the RFS and OS in patients with cervical cancer. Our findings show that patients with an LMR \>2.87 seem to have a significantly longer RFS and OS, which is consistent with the results of other studies involving a variety of malignant tumors.[@b9-ott-8-1355],[@b10-ott-8-1355],[@b19-ott-8-1355] The reason for this result may be that, similar to the NLR and dNLR, the LMR is believed to reflect a disorder of the antitumor immune system in cancer patients. The relationship between the LMR and the age at diagnosis (*P*\<0.001), tumor stage (*P*=0.012), and parametrial involvement (*P*=0.022) may also contribute to the prognostic value of the LMR. A low LMR may reflect a more serious immune system disorder and an advanced stage of cervical cancer.

In the univariate analysis, our study indicated that the AMC and ALC were significantly correlated with the clinical outcome in stage Ib1--IIa cervical cancer patients. We wondered whether the AMC and ALC had prognostic values similar to those of their ratio, the LMR. By applying ROC curves and a multivariate Cox regression analysis, we found that all three of these biomarkers have similar prognostic effects and that the LMR was slightly superior for predicting both the recurrence of and death from cervical cancer. The reason for its superiority may be that the LMR is derived from both the ALC and the AMC. An increased ALC was a good prognostic factor for recurrence and survival, whereas an increased AMC was a poor prognostic factor. Thus, the LMR may expand the prognostic value of these counts.

As with all retrospective studies, our study could not completely avoid a selection bias. We attempted to reduce the interference by excluding patients with an active infection, chronic inflammatory disease, or unavailable follow-up data. One of the strengths of our study is the short time interval between admission and blood collection, which occurred within 2 days after admission, thereby excluding any possible interference of treatment or drugs that could affect local inflammation. The relatively large sample size was also an advantage.

Conclusion
==========

In summary, we have proven that an elevated LMR is a potential prognostic marker for patients with primary operable cervical cancer. Because this ratio can be easily obtained with a routine blood test, the LMR may be a useful and inexpensive biomarker for predicting the clinical outcome. A prospective study is warranted for further validation of our findings.
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![Receiver operating characteristic curves for the ALC, AMC, and LMR for RFS.\
**Notes:** ROC curves were used to maximize the prognostic value of the LMR for RFS and OS. The ROC curve is actually composed of the two-dimensional coordinates of the point group N (sensitivity, 1 − specificity) plotted curves. Each point represents both the sensitivity and specificity of a test marker. The Youden index (ie, sensitivity + specificity −1), which indicates the maximum potential effectiveness of a biomarker, was chosen as the best diagnostic cutoff value in our paper. Examining RFS, the areas under the curve were 0.576, 0.611, and 0.640 in RFS for ALC, AMC, and LMR, respectively. Diagonal segments are produced by ties.\
**Abbreviations:** ALC, absolute lymphocyte count; AMC, absolute monocyte count; LMR, lymphocyte/monocyte ratio; RFS, recurrence-free survival; ROC, receiver operating characteristic OS, overall survival.](ott-8-1355Fig1){#f1-ott-8-1355}

![Kaplan--Meier curve stratified by the LMR for the RFS.\
**Notes:** An increased LMR is a consistent factor for less recurrence in stage Ib1--IIa cervical cancer patients who undergo radical surgery (*P*\<0.001, log-rank test).\
**Abbreviations:** LMR, lymphocyte/monocyte ratio; RFS, recurrence-free survival.](ott-8-1355Fig2){#f2-ott-8-1355}

![Kaplan--Meier curve stratified by the LMR for the OS.\
**Notes:** An increased LMR is a consistent factor for good prognosis in stage Ib1--IIa cervical cancer patients who undergo radical surgery (*P*\<0.001, log-rank test).\
**Abbreviations:** LMR, lymphocyte/monocyte ratio; OS, overall survival.](ott-8-1355Fig3){#f3-ott-8-1355}

###### 

Baseline patient characteristics

                                  Cases (n=485)   LMR ≤2.87 (n=149)   LMR \>2.87 (n=336)   *P*-value
  ------------------------------- --------------- ------------------- -------------------- -----------
  Age at diagnosis                                                                         \<0.001
    ≤45 years                     239 (49.3%)     108 (72.5%)         131 (39.0%)          
   \>45 years                     246 (50.7%)     41 (27.5%)          205 (61.0%)          
  Pathological type                                                                        0.362
   SCC                            433 (89.3%)     131 (87.9%)         302 (89.9%)          
   Non-SCC                        52 (10.7%)      18 (12.1%)          34 (10.1%)           
  Tumor grade                                                                              0.165
   G1                             50 (10.3%)      19 (12.8%)          31 (9.2%)            
   G2                             261 (53.8%)     85 (57.0%)          176 (52.4%)          
   G3                             174 (35.9%)     45 (30.2%)          129 (38.4%)          
  Depth of stromal invasion                                                                0.386
   \<2/3                          209 (43.1%)     60 (40.3%)          149 (44.3%)          
   ≥2/3                           276 (56.9%)     89 (59.7%)          187 (55.7%)          
  Lymphovascular space invasion                                                            0.098
   Yes                            63 (13.0%)      25 (16.8%)          38 (11.3%)           
   No                             422 (87.0%)     124 (83.2%)         298 (88.7%)          
  Lymph node metastasis                                                                    0.917
   No                             386 (79.6%)     118 (79.1%)         268 (79.8%)          
   1                              53 (10.9%)      15 (10.1%)          38 (11.3%)           
   2                              11 (2.3%)       4 (2.7%)            7 (2.1%)             
    ≥3                            35 (7.2%)       12 (8.1%)           23 (6.8%)            
  Tumor stage                                                                              0.012
   Ib1                            116 (23.9%)     32 (21.5%)          84 (25.0%)           
   Ib2                            210 (43.3%)     54 (36.2%)          156 (46.4%)          
   IIa                            159 (32.8%)     63 (42.3%)          96 (28.6%)           
  Parametrial involvement                                                                  0.022
   Yes                            12 (2.5%)       0 (0%)              12 (3.6%)            
   No                             473 (975%)      149 (100%)          324 (96.4%)          
  Adjuvant therapy                                                                         \<0.001
   None                           107 (22.1%)     47 (31.6%)          60 (17.9%)           
   Radiotherapy                   63 (13.0%)      6 (4.0%)            57 (17.0%)           
   Chemoradiotherapy              315 (64.9%)     96 (64.4%)          219 (65.1%)          

**Abbreviations:** LMR, lymphocyte/monocyte ratio; SCC, squamous cell carcinoma.

###### 

Univariate and multivariate analyses of the association of the prognostic factors and the LMR with RFS

  Factors                         Univariate analysis HR (95% CI)   *P*-value   Multivariate analysis HR (95% CI)   *P*-value
  ------------------------------- --------------------------------- ----------- ----------------------------------- -----------
  Age at diagnosis                                                                                                  
   \<45 years                     1                                 \<0.001     1                                   0.084
    ≥45 years                     0.443 (0.286--0.687)                          0.657 (0.408--1.058)                
  Pathological type                                                                                                 
   SCC                            1                                 0.866                                           
   Non-SCC                        0.965 (0.639--1.458)                                                              
  Tumor grade                                                                                                       
   G1                             1                                 0.024       1                                   0.276
   G2                             1.479 (1.054--2.076)                          1.232 (0.846--1.793)                
   G3                                                                                                               
  Depth of stromal invasion                                                                                         
   \<2/3                          1                                 \<0.001     1                                   0.043
    ≥2/3                          1.574 (1.264--1.961)                          1.398 (1.010--1.935)                
  Lymphovascular space invasion                                                                                     
   Yes                            1                                 \<0.001     1                                   0.073
   No                             2.718 (1.704--4.335)                          1.608 (0.956--2.705)                
  Lymph node metastasis                                                                                             
   No                             1                                 \<0.001     1                                   \<0.001
   1                              1.854 (1.567--2.194)                          1.735 (1.457--2.065)                
   2                                                                                                                
    ≥3                                                                                                              
  Tumor stage                                                                                                       
   Ib1                            1                                 0.015       1                                   0.072
   Ib2                            1.425 (1.072--1.893)                          1.329 (0.975--1.812)                
   IIa                                                                                                              
  Parametrial involvement                                                                                           
   Yes                            1                                 0.385                                           
   No                             0.418 (0.058--2.998)                                                              
  Adjuvant therapy                                                                                                  
   None                           1                                 0.001       1                                   0.816
   Radiotherapy                   1.778 (1.280--2.468)                          0.946 (0.591--1.514)                
   Chemoradiotherapy                                                                                                
  LMR                                                                                                               
    ≤2.87                         1                                 \<0.001     1                                   \<0.001
   \>2.87                         0.373 (0.247--0.563)                          0.439 (0.279--0.693)                

**Abbreviations:** CI, confidence interval; HR, hazard ratio; LMR, lymphocyte/monocyte ratio; RFS, recurrence-free survival; SCC, squamous cell carcinoma.

###### 

Univariate and multivariate analyses of the association of prognostic factors and LMR with the time to OS

  Factors                         Univariate analysis HR (95% CI)   *P*-value   Multivariate analysis HR (95% CI)   *P*-value
  ------------------------------- --------------------------------- ----------- ----------------------------------- -----------
  Age at diagnosis                                                                                                  
   \<45 years                     1                                 0.002       1                                   0.244
    ≥45 years                     0.447 (0.265--0.753)                          0.715 (0.406--1.258)                
  Pathological type                                                                                                 
   SCC                            1                                 0.778                                           
   Non-SCC                        0.928 (0.553--1.557)                                                              
  Tumor grade                                                                                                       
   G1                             1                                 0.007       1                                   0.056
   G2                             1.783 (1.175--2.707)                          1.574 (0.989--2.507)                
   G3                                                                                                               
  Depth of stromal invasion                                                                                         
   \<2/3                          1                                 0.001       1                                   0.063
    ≥2/3                          1.570 (1.208--2.042)                          1.455 (0.980--2.161)                
  Lymphovascular space invasion                                                                                     
   Yes                            1                                 0.002       1                                   0.455
   No                             2.451 (1.392--4.317)                          1.269 (0.679--2.371)                
  Lymph node metastasis                                                                                             
   No                             1                                 \<0.001     1                                   \<0.001
   1                              1.743 (1.425--2.132)                          1.596 (1.292--1.972)                
   2                                                                                                                
    ≥3                                                                                                              
  Tumor stage                                                                                                       
   Ib1                            1                                 0.031       1                                   0.203
   Ib2                            1.454 (1.034--2.046)                          1.271 (0.879--1.838)                
   IIa                                                                                                              
  Parametrial involvement                                                                                           
   Yes                            1                                 0.642                                           
   No                             0.626 (0.087--4.513)                                                              
  Adjuvant therapy                                                                                                  
   None                           1                                 0.004       1                                   0.842
   Radiotherapy                   1.776 (1.199--2.631)                          0.943 (0.532--1.674)                
   Chemoradiotherapy                                                                                                
  LMR                                                                                                               
    ≤2.87                         1                                 \<0.001     1                                   0.001
   \>2.87                         0.381 (0.233--0.622)                          0.417 (0.244--0.714)                

**Abbreviations:** CI, confidence interval; HR, hazard ratio; LMR, lymphocyte/monocyte ratio; OS, overall survival; SCC, squamous cell carcinoma.
